Language:

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population

OncoTargets and therapy, 2020-01, Vol.13, p.867-876 [Peer Reviewed Journal]

2020 Petrillo et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020 Petrillo et al. 2020 Petrillo et al. ;ISSN: 1178-6930 ;EISSN: 1178-6930 ;DOI: 10.2147/ott.s229813 ;PMID: 32099391

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
Author: Petrillo, Angelica ; Tirino, Giuseppe ; Zito Marino, Federica ; Pompella, Luca ; Sabetta, Rosalaura ; Panarese, Iacopo ; Pappalardo, Annalisa ; Caterino, Marianna ; Ventriglia, Anna ; Laterza, Maria Maddalena ; Morgillo, Floriana ; Orditura, Michele ; Ciardiello, Fortunato ; Franco, Renato ; De Vita, Ferdinando
Subjects: Asians ; Cancer ; Cancer metastasis ; Cancer patients ; Care and treatment ; Chemotherapy ; Clinical trials ; Diseases ; immune-checkpoint inhibitors ; Immunotherapy ; Ipilimumab ; Metastasis ; msi ; Nivolumab ; Original Research ; pd-l1 ; Stomach cancer ; third line ; Toxicity
Is Part Of: OncoTargets and therapy, 2020-01, Vol.13, p.867-876
Description: ATTRACTION-2 trial assessed the role of Nivolumab as a new standard treatment for Asian patients with pretreated metastatic gastric cancer (mGC). The aim of this analysis was to evaluate the safety and efficacy of Nivolumab in a real-life Western population, considering the lack of evidence to date. Patients progressed after ≥2 chemotherapy regimens and able to receive Nivolumab (3 mg/kg q14) were eligible for the analysis. 16 patients received Nivolumab as third (81.3%) or fourth line (18.7%) from September 2017 to July 2019. The safety was in line with the literature and only one patient discontinued treatment due to persistent hematological toxicity. Overall response rate and disease control rate were 18.7% and 31.2%, respectively. Median duration of response was 5 months. With a median follow-up of 21 months, median OS was 6 months (7, 21 and 22 months in the responders) and median PFS 3 months. PD-L1 and microsatellite status were retrospectively collected in 12 patients. All the major responders were MSI, although no statistically significant difference in OS or PFS was observed according to molecular analysis. Nivolumab is feasible and effective in Western patients with mGC. Further investigation is urgently needed also in non-Asians.
Publisher: New Zealand: Dove Medical Press Limited
Language: English
Identifier: ISSN: 1178-6930
EISSN: 1178-6930
DOI: 10.2147/ott.s229813
PMID: 32099391
Source: GFMER Free Medical Journals
PubMed Central
DOVE Medical Press Journals
ROAD: Directory of Open Access Scholarly Resources
ProQuest Central
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population

2020 Petrillo et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020 Petrillo et al. 2020 Petrillo et al. ;ISSN: 1178-6930 ;EISSN: 1178-6930 ;DOI: 10.2147/ott.s229813 ;PMID: 32099391

Searching Remote Databases, Please Wait